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ABSTRACT
The short-chain fatty acid butyrate plays an essential role in colonic mucosa homeostasis through the capacity to block the cell cycle, regulate
differentiation and to induce apoptosis. The beneﬁcial effect of dietary ﬁbers on preventing colon cancer is essentially mediated through
butyrate, derived from luminal fermentation of ﬁbers by intestinal bacteria. In epithelial cells of the colon, both in normal and colon cancer
cells, the expression of several genes is positively or negatively regulated by butyrate likely through modulation of histone acetylation and
thereby affecting the transcriptional activity of genes. Calretinin (CALB2) is a member of the EF-hand family of Ca2þ-binding proteins and is
expressed in a majority of poorly differentiated colon carcinoma and additionally in mesothelioma of the epithelioid and mixed type. Since
CALB2 is one of the genes negatively regulated by butyrate in colon cancer cells and butyrate decreases calretinin protein expression levels in
those cells, we investigated whether expression is regulated via putative butyrate-responsive elements (BRE) in the human CALB2 promoter.
We identiﬁed two elements that act as butyrate-sensitive repressors in all colon cancer cell lines tested (CaCo-2, HT-29, Co-115/3). In contrast,
in cells of mesothelial origin, MeT-5A and ZL34, the same two elements do not operate as butyrate-sensitive repressors and calretinin
expression levels are insensitive to butyrate indicative of cell type-speciﬁc regulation of the CALB2 promoter. Calretinin expression in colon
cancer cells is negatively regulated by butyrate via a bipartite BRE ﬂanking the TATA box and this may be linked to butyrate’s
chemopreventive activity.
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C olorectal cancer is one of the main causes of cancer-relatedmortality in Western societies and epidemiological, clinical
and experimental evidence support the hypothesis that diet is an
important factor for the modulation of this disease [Reddy,
2000]. Different classes of molecules are discussed as promising
chemopreventive agents and comprise calcium, vitamin D, folate
[Lamprecht and Lipkin, 2003] and short chain fatty acids (SCFA)
including butyrate [Siavoshian et al., 1997]. The latter is the product
of the luminal fermentation of dietary ﬁbers by intestinal bacteria
and is found in millimolar concentrations in the luminal milieu in
the colon. It is taken up by epithelial cells by the colonic luminal-
membrane butyrate transporter, MCT1 [monocarboxylate transpor-
ter 1; Daly et al., 2005] and serves as the principal energy source for
these cells [Roediger, 1982]. Previous studies have shown that high-
ﬁber diets decrease the incidence of colorectal cancer and SCFAs
including butyrate are involved in the regulation of cell growth,
differentiation and apoptosis. Butyrate has the capacity to modulate
histone acetylation by acting as a potent inhibitor of histone
deacetylases (HDACs) and thereby modiﬁes transcriptional activity
of several genes. Described effects of butyrate include the
downregulation of cyclin D1 (CCND1) [Lallemand et al., 1996],
the induction of the inhibitor of cyclin-dependant kinases p21
WAF1/Cip1 (CDKN1A) [Nakano et al., 1997] and the peroxisome
proliferator activated receptor gamma (PPARg) [Schwab et al., 2006]
ﬁnally leading to the blockage of the cell cycle and the induction of
apoptosis in colon cancer cells. The mediators of this effect are still
poorly characterized, but in recent years, several genes have been
identiﬁed, which are regulated in a butyrate-dependent manner.
These include the zinc ﬁnger transcription factor Kru¨ppel-like
factor-4 (KLF-4) [Chen et al., 2004], intrinsic trefoil factor (ITF) [Tran
et al., 1998], glycoprotein hormone a-subunit (GPHa) [Haas et al.,
1999], the insulin-like growth factor binding protein-3 (IGFBP-3)
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[Tsubaki et al., 2002], transient receptor potential vanilloid type 6
(TRPV6) [Fukushima et al., 2009] and the CaBP calbindin D-28k
(CALB1) [Gill and Christakos, 1993].
In most cases, the modulation occurs through Sp1 sites or
putative butyrate-responsive elements (BRE) in the promoter
regions of these genes. These elements mainly act as enhancers
and most often butyrate induces expression as shown for KLF-4,
WAF1/Cip1, GPHa, IGFBP-3, TRPV6, CB and PPARg, but may also
act as repressors as shown for CCND1.We had previously shown that
the addition of butyrate to the colon cancer cell lineWiDr blocks cell
growth, concomitant with a decrease in the expression of the Ca2þ-
binding protein calretinin (CR) [Schwaller and Herrmann, 1997]. CR
is normally expressed in a subset of neurons in the central and
peripheral nervous system [for a review, see Baimbridge et al., 1992]
and additionally in other speciﬁc cell types of selected organs and
tissues (e.g., testis, ovary). The precise physiological role of CR in
these cells is as yet unknown, but a role of CR in regulating neuron
excitability and associated cerebellar function has been demon-
strated before [Bearzatto et al., 2006]. Aberrant CR expression is
observed in a majority of mesotheliomas of the epithelioid and
mixed type [Doglioni et al., 1996; Gotzos et al., 1996b] and in a large
proportion (>65%) of poorly differentiated (GIII) colon tumors
[Gotzos et al., 1999]. Many colon cancer cell lines used as models to
investigate tumorigenesis (e.g., HT-29, WiDr), express high levels of
CR [Gotzos et al., 1996a]. A role for CR in tumor biogenesis was
postulated based on two ﬁndings: I) Downregulation of CR by
antisense methods blocks the cell cycle at G1/S and leads to
increased apoptosis [Gander et al., 1996] closely resembling the
effects of butyrate and II) Overexpression of CR or the alternatively
splice product CR-22k [Schwaller et al., 1995] increases the
resistance of the CR-negative cell line Caco-2 towards butyrate-
induced growth inhibition and differentiation [Marilley et al., 2001].
Thus, we investigated whether the promoter region of the CALB2
gene contains butyrate-responsive elements (BRE) acting as
transcriptional repressors and whether these putative elements
are functional in different types of CR-positive cells including colon
cancer cells and cells of mesothelial origin. Our results demonstrate
the presence of six putative BREs in the CALB2 promoter. BRE5 and
BRE6 (position 115 to 104 and 67 to 58 nucleotides before
the start codon) embracing the TATA box appear to be the essential
elements conferring repression of CR expression in colon cancer
cells. These elements act as transcriptional repressors selectively in
colon cancer cells, but not in cells of mesothelial origin.
MATERIALS AND METHODS
CELL LINES, CELL CULTURING, TRANSFECTION EXPERIMENTS,
AND TREATMENT WITH SODIUM BUTYRATE
The colon carcinoma cell lines Caco-2 (HTB-37), HT-29 (HTB-38)
and WiDr (CCL-218) as well as the SV40-immortalized mesothelial
cell line MeT-5A (CRL-9444) were obtained from American Type
Culture Collection (ATCC, Rockville, MD). The colon carcinoma cell
line Co-115/3 [Carrel et al., 1976] and the mesothelioma cell line
ZL34 [Schmitter et al., 1992] have been used in previous studies and
were kept frozen as a stock at 1458C [Gotzos et al., 1996a; Saydan
et al., 2001]. All cell lines were cultivated as described before at
378C, in an atmosphere containing 5% CO2, 95% air and with a
relative humidity of 95%. The following media were used: for
WiDr cells, EF medium, a mixture (1:1) of EMED (an enriched
Dulbecco’s modiﬁed Eagle’s medium) and FMED (modiﬁed Ham’s
F-12 nutrient mixture); for Co-115/3 and for HT-29: McCoy’s
medium; for Caco-2: MEM with Earle’s BSS; for MeT-5A: D-MEM/
F-12 (1:1)þGlutaMax (Gibco, Invitrogen AG, Basel, Switzerland)
and for ZL34 cells: RPMI 1640 medium (Gibco) with 2mM
L-glutamine. All media were supplemented with 10% fetal calf
serum, 104 U/L penicillin and 104mg/L streptomycin. The cells were
regularly passaged by trypsinization (0.25% trypsin in Ca2þ
and Mg2þ free phosphate-buffered saline, CMF-PBS, pH 7.2).
Trypsinisation of all lines was performed when conﬂuency reached
approximately 70–80%. The different cell lines were treated with
various sodium butyrate concentrations (NaBt; Sigma, Buchs,
Switzerland; 0.1–10mM; see Results Section) for various periods by
adding aliquots of a 1M stock solution (dissolved in CMF-PBS) to
the culture media.
ISOLATION OF GENOMIC DNA
For the isolation of genomic DNA or protein extracts, cells were
trypsinized, centrifuged (1,000g, RT, 3min), and pelleted cells were
washed twice with CMF-PBS. Genomic DNA was isolated from cell
pellets or from a small piece of tissue from a colon biopsy as
described before [Vonlanthen et al., 2007] using standard methods.
DNA (0.5mg) was used to amplify different parts of the promoter
regions of the human CR gene (for details and primer sequences, see
Fig. 1). Most PCR primers contain restriction sites allowing the
directional cloning of the various fragments in the plasmid pGL3-
Promotor (pGL3-P); Promega; # U47298; Wallisellen, Switzerland.
The ampliﬁed PCR fragments cloned in the reporter plasmid were
veriﬁed by restriction analysis and by sequencing of the insert
(Microsynth AG, Balgach, Switzerland). For transfection experi-
ments, Midi- or Maxiprep DNA (ca. 300–500mg) was isolated using
the Wizard Plus kit (Promega, Wallisellen, Switzerland).
CONSTRUCTION OF DELETION AND MUTATION VARIANTS OF
THE HUMAN CR PROMOTER
A series of promoter mutants containing up to six putative butyrate-
responsive elements (BREs) were constructed using standard
techniques such as amplifying PCR fragments from genomic DNA
and cloning of restriction enzyme fragments in the reporter plasmid
pGL3-P (Promega; # U47298; Wallisellen, Switzerland). This
plasmid contains a multi-cloning site (MCS), followed by a SV40
promoter and the luciferase cassette (lucþ) is followed by an SV40
late poly (A) signal. Details for the construction of the various
reporter plasmids are listed below and are schematically shown in
Figure 1 and Table I. As template for PCR, genomic DNA isolated
from the colon cancer cell line WiDr was used. Using the plasmid
containing all six elements (BRE1–6/pGL3-P), additional constructs
were produced by digesting the BRE1–6/pGL3-P with SacI and
either SmaI, PmlI, or ApaI (Fig. 1B), the SacI site was ﬁlled by
Klenow fragment generating blunt ends and re-ligating the
vector by adding T4 Ligase. This yielded the plasmids BRE2–6/
pGL3-P, BRE4–6/pGL3-P, and BRE5–6/pGL3-P, respectively. All
plasmids were analyzed by restriction enzyme digestions and DNA
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sequencing and were found to contain the identical sequences of the
CALB2 promoter as in the PubMed database. In the plasmid BRE5–6/
pGL3-P, the putative BREs 5 and 6 were individually mutated
yielding the plasmids BRE5mut-6/pGL3-P and BRE5–6mut/pGL3-P
(Fig. 1C). For this 50 and 30 PCR primers (length 40 bp) containing the
mutation in their 30 and 50 end, respectively were used together with
primers in the 50 and 30 ﬂanking region of the vector to produce the 2
PCR fragments with the mutated BREs at their 50 or 30 end. The
puriﬁed PCR fragments (by agarose gel electrophoresis) were
mixed at a 1:1 stochiometry and used as PCR template using
Fig. 1. A: Primer sequences used to amplify PCR fragments containing a various number of putative BREs. Sequences not part of the CALB2 promoter region are in italics and
the restriction site SacI is underlined. Primer sequences of the (þ) strand or the () strand are also highlighted in the CALB2 promoter sequence (B; gray boxes). B: The CALB2
promoter region containing the six putative BREs (boxed) is shown from pos. 823 to pos. þ77 (ATG¼þ1). The boxed nucleotides conferring to the consensus sequence
GCnGGnTCCA are marked in bold. The restrictions sites used for the deletion mutants are in italics and underlined. The TATA-box region and the start codon in exon 1 are
capitalized and marked bold. C: The sequences of the mutated elements BRE5mut and BRE6mut (boxed) ﬂanking the TATA box (bold, italics) are shown. Underneath depicted are
the original promoter sequences containing the BREs 5 and 6 (underlined; nucleotides conferring to the consensus sequence are marked in bold).
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the outer 50 and 30 primers. The generated fragment was digested
with NotI and XhoI and inserted into the same sites in pGL3-P. The
correctness of the inserts in the new plasmids was veriﬁed by DNA
sequencing.
TRANSFECTION OF CELLS WITH pGL3-P REPORTER PLASMIDS
AND CONTROL PLASMIDS: LUCIFERASE ASSAY
AND b-GALACTOSIDASE ASSAY
The three colon cancer cell lines Caco-2, HT-29, and Co-115/3 and
the 2 cell lines of mesothelial origin (MeT-5A and ZL34) were
transfected with Lipofectamin 2000 (Invitrogen, Lubioscience,
Lucerne, Switzerland) following the supplier’s recommendations.
We used 6-well plates (10 cm2/well) and cells were seeded at a
density of 104 cells/cm2. Transfection with the various plasmids
(2mg) and the control plasmid pSV-b-galactosidase (2mg; Promega;
#E1081) that contains the SV40 promoter and enhancer elements
and the lacZ-cDNA coding for b-galactosidase were carried out at a
conﬂuency of 50–70%. The next day the medium was supplemented
with sodium butyrate (ﬁnal concentration: 0.1–5mM NaBt for the
cell lines Caco-2, HT-29 and Co-115/3, respectively) for 48 h. The
cells were then harvested by scraping from the 6-well plates, cells
were washed twice with CMF-PBS and soluble proteins were
extracted as described before [Marilley et al., 2001]. The protein
concentration in the extracts was determined using the RC DC
Protein Assay kit (Bio-Rad Laboratories AG, Reinach, Switzerland).
From these, 10ml containing 2–10mg protein were used for the
luciferase assay using the luciferase substrate from Promega and
values are expressed per microgram of protein; all samples were
measured in triplicates using a Luminometer TD-20/20 (Turner
Biosystems, Sunnyvale, CA) with an integration time of 10 s. For
the normalization of the luciferase assay data, cells were co-
transfected with the control plasmid pSV-b-galactosidase (Pro-
mega; #E1081). Through the activity of b-galactosidase, the
substrate 4-methylumbelliferyl-b-D-galactopyranoside (MUG,
Sigma) is cleaved and the product methylumbelliferone is monitored
at 460 nm when excited at 360 nm. For each sample the ratio
luminescence/b-Gal activity was calculated. From sample pairs
(e.g., the same cell type NaBt) the fold induction induced by
butyrate was calculated and the value for the control reporter
plasmid without insert (pGL3-P) was set to 100% for each
experiment. This was to standardize the data and to eliminate
inter-experimental variations due to cell conﬂuency and other cell
culture related variability.
SDS–PAGE AND WESTERN BLOTS
For the Western blots, proteins were separated by SDS–PAGE on
12% polyacrylamide gels, transferred to membranes using a
semi-dry protocol as described before [Racay et al., 2006]. The
antibody CR7696 [Schwaller et al., 1993] was used to detect CR in a
semi-quantitative way using the ECL system as described before
[Racay et al., 2006].
GROWTH CURVES DETERMINED BY MTT ASSAY AND
FLUORIMETRIC DNA ASSAY
Cell proliferation was determined by two methods: the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay
(Thiazolyl blue tetrazolium bromide; #M5655, Sigma, Buchs,
Switzerland) as described before [Schwaller and Herrmann, 1997]
and the Fluorimetric DNA Assay [Rao and Otto, 1992]. In the former,
the accumulation of dark blue formazan crystals inside living cells
after their exposure to MTT is measured photometrically by the
addition of dimethylsulfoxide (DMSO, 100ml/well) that destroys the
cell membrane and solubilizes the formazan crystals. The formazan
concentration is ﬁnally quantiﬁed using an ELISA-plate spectro-
photometer by measuring the absorbance at 540 nm (Dynatec MRX,
Dynatec Produkte AG, Switzerland). For each cell type, a linear
relationship between cell number and optical density is established,
thus allowing an accurate quantiﬁcation of changes in the rate of
cell proliferation. In the second assay, the quantity of DNA per
sample well is determined that is directly proportional to the number
of cells. Cells are seeded in 96-well plates in the presence of various
concentrations of butyrate and incubated for periods of 1–4 days.
After removing the medium andwashing the cells with PBS, cells are
lysed in 10ml SSC buffer (15mM sodium citrate, 150mM NaCl, pH
7.0 containing 0.2% (w/v) SDS) for 10min at RT. SSC buffer without
SDS (90ml) is added and samples are incubated on a rotating shaker
(200 rpm) for 1 h at 378C. From the Hoechst 33258 (Sigma; 861405)
working solution (1mg/ml in SSC buffer), 100ml are added to each
sample, the mixture is incubated in the dark for 15min on the shaker
and then measured on a Promega GloMax Multi Detection System
(Ex./Em.: 350 nm/460 nm).
CELL DEATH ASSAYS
The number of dead cells was determined by the CytoTox-GloTM
Cytotoxicity Assay (Promega) according to the supplier’s recom-
mendations. Brieﬂy, the assay measures a distinct protease activity
released by dead cells that cleaves a luminogenic peptide AAF-
GloTM substrate. MeT-5A (4500 cells/well) and HT-29 (8,000 cells/
TABLE I. Primers and Plasmids Used for the Construction of the Different Plasmids Containing Parts of the Human Calretinin Promoter
Forward primer Restr. site Reverse primer Sites in vectora Size (bp), BREs Plasmid name CALB2 promoter (ATG¼þ1)
HCR50-823 SacI HCR30þ77 SacI, SmaI 900, 1–6 pGL3-P/BRE1–6 823 to þ77
HCR50-823 SacI HCR30470 SacI, BglII 354, 1–3 pGL3-P/BRE1–3 823 to 470
Parental plasmid Fragment del. (bp) Sites in vectora Size (bp), BREs Plasmid name CALB2 promoter (ATG¼þ1)
pGL3-P/BRE1–6 131 SacI, SmaI 769, 2–6 pGL3-P/BRE2–6 692 to þ77
pGL3-P/BRE1–6 217 SacI, PmlI 683, 4–6 pGL3-P/BRE4–6 606 to þ77
pGL3-P/BRE1–6 603 SacI, ApaI 297, 5–6 pGL3-P/BRE5–6 220 to þ77
aSites used in pGL3-P/BRE1–6 to produce deletion mutants BRE2–6, 4–6, and 5–6.
ht
tp
://
do
c.
re
ro
.c
h
4
well) cells were cultured in 96-well plates for 24 h. Various
concentrations of butyrate (0, 2.5, 5, and 7.5mM) were added
for 36 h and the amount of dead cells determined on a
Microplate Luminometer LB96V (Berthold Technologies,
Regensdorf, Switzerland). For the detection of apoptotic cells, the
Caspase-Glo1 3/7 Assay (Promega) was used. In this luminescent
assay, the activity of the caspases 3/7 is determined. The cleavage of
a luminogenic substrate containing the DEVD sequence by caspases
3/7 leads to the production of aminoluciferin that is quantiﬁed on a
Bioluminescence reader (Promega GloMax Multi Detection System).
Other details (cell numbers, incubation times) are as for the
Cytotoxicity Assay, except that apoptosis was assayed 24 h after
addition of butyrate.
RESULTS
EFFECT OF BUTYRATE ON CELL PROLIFERATION AND CALRETININ
EXPRESSION IN THE COLON CARCINOMA CELL LINES Co-115/3,
HT-29, AND Caco-2
In line with previous ﬁndings that addition of butyrate inhibits the
proliferation of the colon cancer cells WiDr [Nakano et al., 1997;
Schwaller and Herrmann, 1997], HT-29 [Iacomino et al., 2001], and
Caco-2 [Marilley et al., 2001], cell proliferation was also diminished
in Co-115/3 cells in a butyrate concentration dependant way
(Fig. 2A). Results were qualitatively the same, whether the MTT
assay, reporting the combined effects of proliferation (cell number)
and metabolic activity of cells or the DNA assay (directly
proportional to the cell number) was used (Fig. 2B). Evidently,
effects of butyrate were less pronounced using the DNA assay, since
in addition to the reduced number of cells, the MTT assay also
reveals the reduced metabolic activity of butyrate-treated cells that
mostly accumulate in G0/G1 of the cell cycle phase [Mariadason
et al., 2000]. In Co-115/3 cells, even at the highest dose tested (5 and
4mM), proliferation was not completely blocked (Fig. 2A,B,
respectively). At the same butyrate concentrations (1–4mM),
inhibition of proliferation evidenced with the DNA assay was
clearly stronger in HT-29 cells compared to Co-115/3 cells (Fig. 2C);
and already 1mM was sufﬁcient to almost completely block
proliferation of Caco-2 cells (Fig. 2D). Interestingly, this inversely
Fig. 2. Effect of butyrate on cell proliferation and correlation with CR
expression. A: Representative growth curves of Co-115/3 cells in the presence
of butyrate (1–5mM) treated for 6 days. Cell cultures treated with up to 1mM
butyrate reached near-conﬂuence at 3 days and were thus not maintained for
6 days. A concentration-dependent decrease in the MTT signal was observed,
but even at 5mM, proliferation was not completely blocked. B: Growth curves
of butyrate-treated Co-115/3 cells determined by DNA assay (1–4mM; for up
to 4 days); symbols and line types for the different butyrate concentrations are
the same as in (A). Like in (A) the ﬂuorescence signal, proportional to the cell
number (in arbitrary units; A.U.), decreased in a butyrate concentration-
dependent manner. Note that the decrease in MTT signal was more pronounced
than in the DNA assay, since the MTT assay additionally takes into account the
decreased metabolic activity of butyrate-treated cells. C: DNA assay with
butyrate-treated HT-29 cells. The symbols and line types for the different
butyrate concentrations are identical as in (A). The growth-inhibiting effect of
butyrate was stronger in HT-29 than in Co-115/3 cells. D: Growth curves for
Caco-2 cells determined by MTT assay; at concentrations >0.75mM butyrate,
proliferation was almost completely blocked. The effect of 2mM butyrate on
HT-29 proliferation is shown in the inset (open circles). Note that the effect is
again more pronounced in the MTT assay as compared with the DNA assay;
compare to curve (2mM; triangles, dashed line) in (C). E: CR expression levels
in Co-115/3, Caco-2 and HT-29 cells determined by Western blot analysis. A
similar amount (1mg) of soluble protein was loaded; the amount of CR is at
least twofold higher in Co-115/3 than in HT-29 cells. A weak speciﬁc CR signal
for Caco-2 cells is only seen when at least 50–100mg protein is loaded (not
shown).
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correlates with the expression levels of CR: basal expression levels
were highest in Co-115/3 cells, followed by HT-29 cells and CR
levels in Caco-2 cells were extremely low, in general below the
detection limit of Western blot analysis [Fig. 2E and Gotzos et al.,
1996a]. In the two cell lines with detectable CR expression levels, the
addition of butyrate clearly downregulated CR expression. A semi-
quantitative analysis of Western blot membranes indicated an
approximately 80% downregulation of CR in HT-29 cells with
>2mM butyrate after 6 days, while downregulation in Co-115/3
was less pronounced, approximately 50% (Fig. 3A). The results
indicate that CR expression is negatively regulated by butyrate in
colon cancer cells and thus we searched for elements in the promoter
region of CALB2 that might confer the repressive action of butyrate.
THE PROMOTER REGION OF THE HUMAN AND RODENT
CALB2 GENES CONTAINS SIX PUTATIVE
BUTYRATE-RESPONSIVE ELEMENTS
Since treatment of colon carcinoma cells with butyrate leads to a
down-regulation of CR [Schwaller and Herrmann, 1997; Marilley
et al., 2001] we tested the hypothesis that the CALB2 gene could be
directly regulated in a butyrate-dependant manner. For the closely
related Ca2þ-binding protein calbindin D-28k (human gene
symbol CALB1), a butyrate-responsive element was identiﬁed in
the 50 ﬂanking region of the mouse CALB1 gene between 180 and
150 that binds speciﬁcally to nuclear factors from butyrate-treated
Ros 17/2.8 cells [Gill and Christakos, 1993]. In these cells, the
butyrate-responsive element acts as a genetic element acted upon by
enhancer binding proteins and the authors proposed this mechanism
to lead to the enhanced expression of calbindin D-28k by butyrate.
Similarly, the transcription of the mRNA of the glycoprotein
hormone a-subunit gene (GPHa) is upregulated by butyrate and
involves a BRE acting as an enhancer [Haas et al., 1999]. Analysis of
previously described BREs for CALB1, GPH-a, the intestinal trefoil
factor (ITF) [Tran et al., 1998], the IGF-binding protein-3 (IGFBP-3;
[Tsubaki et al., 2002]) and transient receptor potential vanilloid type
6 (TRPV6) resulted in a consensus sequence of 10 bp with highly
conserved nucleotides at positions 1, 2, 4, 5, 8–10 (Fig. 4A,B), the
ﬁrst half often overlapping with putative Sp1 sites. A search in
PubMed resulted in the identiﬁcation of additional promoter regions
of genes reported to be affected by butyrate (Fig. 4A). In the CALB2
promoter region between823 andþ77 (ATG¼ 1) we found 6 DNA
regions named BRE1–6 matching the consensus sequence to various
degrees (Fig. 4C). Further comparison with the CALB2 promoter
regions of mouse and rat revealed three elements (2, 5, and 6) to be
highly conserved between the three species (Fig. 4C). In addition, the
nucleotide preceding the putative BREs (position 0) was highly
conserved between human, rat and mouse CALB2. Nonetheless, this
nucleotide was not well conserved between putative BREs 1–6 and
also previously reported BREs (Fig. 4A) indicating that the
nucleotide in this position is probably not an essential element
(nucleotide) of the BRE.
BRE5 AND BRE6 ACT AS REPRESSOR ELEMENTS IN
COLON CANCER CELLS
Since we hypothesized that the putative BREs in the CALB2 gene
might act as repressors, the plasmid pGL3-P containing a SV40
minimal promoter was selected. A series of plasmids were
constructed containing various numbers of the six putative BREs
and the functionality of the six putative BRE elements in the CALB2
promoter were tested in the cell lines Caco-2, HT-29, and Co-115/3.
The most detailed analysis were carried out in Caco-2 cells, where
transfection efﬁciency is superior (40–60%) compared to the other
two cell lines (typically <1%). In Caco-2 cells, a 12.7 0.5-fold
(mean SEM) increase in luciferase activity was seen with the
control plasmid pGL3-P, while transfection with the plasmid pGL3-
BRE1–6 containing all six elements led to an approximately 40%
decrease (8.9 1.8-fold induction; Dunnett’s test P< 0.05) in
luciferase activity when compared to pGL3-P alone (Fig. 5A,B).
Similar results were found with plasmids containing BREs 2–6, 4–6,
and 5–6 (for all groups, P< 0.05), while the luciferase activity with
the plasmid containing BREs 1–3 was essentially identical to pGL3-P
indicating that only the region containing elements BRE 5 and 6
functions as a repressor. Practically identical results with plasmids
pGL3-BRE1–3, pGL3-BRE5–6 and the control pGL3-P were obtained
in the colon cancer cell lines HT-29 and Co-115/3 (Fig. 5C), although
due to low transfection efﬁciency, variability was larger than in the
Caco-2 cells. Thus, in all colon cancer cells tested, the region
containing BREs 5 and 6 repressed the butyrate-induced luciferase
activity.
To further narrow down the putative BREs, plasmids containing
mutations in either the BRE5 (pGL3-BRE5mut-6) or BRE6 (pGL3-
BRE5-6mut) were constructed and results are presented in
Figure 5D. In the luciferase assays, the activity of the control
plasmid pGL3-P was set at 100%; 100 0.9 (Mean SEM; n¼ 38
samples). For pGL3-BRE5–6 the values were 60.1 2.2 (n¼ 33)
Mutations in BRE5 restored the luciferase activity approximately
half way to 79.1 2.5; n¼ 31), that is, approximately 50% of the
repression mediated by pGL3-BRE5–6 was lost. Also the luciferase
activity of a plasmid with mutations in BRE6 had a similar effect, the
butyrate-induced repression was diminished to 82.1 6.1; n¼ 9.
When combining the effects of mutations in both BRE 5 and 6, the
Fig. 3. Western blot analysis of CR in butyrate-treated cells. A: CR down-
regulation by butyrate in Co-115/3 and HT-29 cells. A butyrate concentration-
dependent decrease in CR levels 6 days after treatment was evident in both cell
lines; down-regulation was stronger in HT-29 cells. For HT-29 cells, two blots
are shown: the upper one was developed with ECL using speciﬁc ECL-ﬁlms, the
lower one was acquired using a Phosphoimager system resulting in a more
‘‘pixeled’’ image. Quantiﬁcation of bands yielded similar results. B: CR detec-
tion in cell extracts from the mesothelial cell line MeT-5A. From left to right:
control (untreated), treatment with 1 or 2mMNaBt. No signiﬁcant differences
were evident after butyrate treatment.
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Fig. 4. A: Putative butyrate-responsive elements (BRE) in the promoter regions of genes regulated by butyrate (for abbreviations, see below). The consensus sequence
embracing 10 nucleotides is marked in red as well as nucleotides in the promoter region of the various genes conferring to the consensus sequence. Nucleotides found more than
10 times in the total of 17 sequences are additionally marked in bold. The sequences of putative BREs reported in previous studies are boxed and often overlap with Sp1 sites
(for details, see results). The numbers of nucleotides conferring to bold nucleotides within the consensus BRE are shown in the right lane, numbers in brackets also include the
less-well conserved nucleotides of the consensus. In the gamma globin gene, additional G (blue) preceding the consensus sequence was identiﬁed as recognition sites
for proteins binding to the consensus (for details, see Results Section). B: At each of the 10 positions of the consensus, the distribution of nucleotides of the 17 analyzed
sequences is shown; nucleotides most often present in that position are marked in bold and nucleotides occurring more than 10 times are boxed. C: Comparison of the six
putative BREs in the promoter region of the CALB2 gene in different species. Highly consensus nucleotides are marked in bold, the ones conferring to the consensus sequence are
in capitals and the nucleotides not conferring to the consensus are in miniscule. The number of nucleotides conferring to the consensus sequence of each BRE is listed.
Abbreviations of genes and gene symbols: MT2A, Metallothionein IIA; CCND1, cyclin D1; TFF3, intestinal trefoil factor; ALPPL2, alkaline phosphatase, placental-like 2; CDKN1A,
cyclin-dependent kinase inhibitor 1A (p21, Waf1) [Nakano et al., 1997]; KLF4, Kruppel-like factor 4 (a zinc ﬁnger-containing transcription factor with diverse regulatory
functions in cell growth, proliferation, differentiation, and embryogenesis [Chen et al., 2004]; CGA, glycoprotein hormone, alpha polypeptide (GPHA1, GPHa,); IGFBP3, insulin-
like growth factor binding protein 3 [Tsubaki et al., 2002]; HBG1, hemoglobin, gamma A; TRPV6, transient receptor potential vanilloid type 6 [Fukushima et al., 2009]; SCFA,
Short-chain fatty acid.
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luciferase activity reached again close to 100%. Thus, the two
elements BRE5 and BRE6 contributed to the repression and each of
the elements had a similar contribution to the effect.
BUTYRATE AFFECTS SURVIVAL OF MESOTHELIAL AND
MESOTHELIOMA CELLS, BUT BREs 5 AND 6 DO NOT ACT AS
BUTYRATE-DEPENDANT REPRESSORS
Aberrant CR expression occurs in certain colon cancer cell lines
[Gotzos et al., 1996a] and in a majority of GIII colon tumors [Gotzos
et al., 1999], but is also observed in almost all mesotheliomas of the
epitheloid and the mixed type [Doglioni et al., 1996; Gotzos et al.,
1996b]. Thus, we tested whether butyrate also affects proliferation of
mesothelial and mesothelioma cells as well as CR expression levels
in these cells. For this, we used the mesothelial cell line MeT-5A and
the mesothelioma cell line ZL34 [Saydan et al., 2001]. The MTT
signal in butyrate-treated MeT-5A cells transiently decreased in a
concentration-dependent manner and similar results were obtained
for ZL34 cells (not shown). However, unlike in colon cancer cells,
where butyrate treatment leads to a prolonged blockage of cell
proliferation and morphological changes typical for differentiation
(e.g., ﬂattening of the cells, appearance of brush border [Cargnello
et al., 1996]), the decreased MTT signal in the cells of mesothelial
origin was principally caused by a rather massive cell death (necrosis
and apoptosis) evidenced by detached and ﬂoating cells (not shown).
Many remaining cells were characterized by a retraction, that is,
reduced cell–cell contacts, condensed and pycnotic nuclei,
membrane blebbing, all signs of apoptotic cell death (Fig. 6B). Cell
death was quantiﬁed and compared in cells of mesothelial (MeT-5A)
and of epithelial (HT-29) origin subjected to maximally 7.5mM
butyrate for 36 or 24 h (Fig. 6D,E, respectively). Both, the amount of
necrotic (Fig. 6D) and apoptotic (Fig. 6E) cells increased in a dose-
dependent manner in MeT-5A cells, while cell death was only
minimally increased in HT-29 cells. As reported before in the closely
related WiDr cells [Schwaller and Herrmann, 1997], butyrate
treatment results in HT-29 cells forming either compact cell clusters
or individual large cells characterized by a ﬂattened morphology.
Interestingly, a fraction of MeT-5A cells survived the treatment and
continued to grow even in the presence of up to 10mM butyrate. The
Fig. 5. Luciferase reporter assay with various parts of the CALB2 promoter region. A: The plasmid pGL3-P containing a SV40 minimal promoter (black box) was used as a
control. Various parts of the CALB2 promoter region containing putative BREs were cloned upstream of the SV40 minimal promoter. The fold induction of luciferase activity due
to butyrate treatment of Caco-2 cells is reported. B: For the normalization, the value of the control plasmid pGL3-P was set to 100%. Using the four plasmids containing BREs 5
and 6 (dark gray box), the luciferase activity was decreased by approximately 40%, while the plasmid containing BRE1–3 showed a similar activity as the control plasmid. A two-
way ANOVA revealed the six groups to be different ( P< 0.0001). For comparing the effect of individual plasmids with the control (pGL3-P), Dunnett’s test was used, a more
conservative test than pairwise t-tests, because it takes into account multiple comparisons. The results show that all plasmids containing BRE5 and 6 are signiﬁcantly different
from the control plasmid (for all plasmids P< 0.05), while this is not the case for the plasmid containing BRE1–3. The results indicate that the CALB2 promoter region
containing BRE5 and 6 acts as a repressor in Caco-2 cells. C: The CALB2 promoter region containing BRE5 and 6 acts as a repressor in all colon cancer cells tested (Caco-2, HT-29
and Co115/3), but not in the mesothelial cell line MeT-5A. The repressor activity is not enclosed in the region containing BRE1–3. The larger standard deviations observed in cell
lines HT-29, Co115/3, and MeT-5A are due to the rather poor transfection efﬁciencies compared to Caco-2 cells. D: Introducing mutations in BRE5 (light gray) and BRE6 (dark
gray; for details, see Fig. 1C) increased the luciferase activity by approximately 20% for each BRE. Adding the effects brought about by the mutations in either BRE5 or BRE6
(BRE5 and 6 mut) resulted in a luciferase activity as observed with the control plasmid pGL3-P.ht
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morphology of surviving cells (Fig. 6C) again resembled the one of
untreated cells (Fig. 6A), although some differences in cell shape
persisted. Thus, the effect of butyrate on mesothelial cells is rather a
cytotoxic (necrotic and apoptotic; Fig. 6D,E) than a differentiation-
inducing one. Concomitantly, CR expression levels in MeT-5A cells
were not affected by butyrate at a concentration of 1 or 2mM, a dose
not leading to massive cell death; this is seen by the essentially
unchanged Western blot signals in cells treated with 1 or 2mM
butyrate (Fig. 3B). At 5mM butyrate, the minute number of MeT-5A
cells surviving this treatment after 5–6 days did not allow to obtain
enough protein for Western blot analysis. On average CR expression
levels were marginally increased (<20%) after treatment of cells
with 1mM NaBt and slightly decreased (<20%) in cells treated with
2mM (P> 0.1 vs. control for both NaBt concentrations). The
luciferase activity in NaBt-treated MeT-5A cells was only minimally
increased (1.5- to 1.8-fold compared to >10-fold in colon cancer
cells) and when expressed in relative terms, no differences were
observed when the constructs with BRE1–3 (1.7 0.5) and BRE5–6
(1.8 0.1) were compared to the control plasmid pGL3-P without
the CALB2 promoter region (1.8 0.2). The fold induction was even
lower in the mesothelioma cell line ZL 34 cells: 1.3 0.3 for the
control plasmid pGL3-P, 0.9 0.3 for the plasmid containing
elements BRE5–6 (P> 0.1). Thus, butyrate has a rather cytotoxic
effect on cells of mesothelial origin (MeT-5A and ZL34) and the BRE
elements 5 and 6 in the CALB2 promoter do not act as functional
repressors of CR expression in these cells.
DISCUSSION
Butyrate present at millimolar concentrations in the lumen of the
digestive tract including the colon is taken up by the epithelial cells
and is used as a primary source for energy metabolism, but
additionally acts as an agent inducing differentiation of these cells.
Thus, a diet rich in dietary ﬁbers leading to elevated butyrate
levels decreases the incidence of colon tumors evidenced in
epidemiological studies [reviewed in Reddy, 2000]. Butyrate acts as
an established histone deacetylase inhibitor by favoring an active
chromatin conﬁguration. A number of genes is positively or
negatively regulated by butyrate and in the last years, several studies
aimed to elucidate the genes and moreover gene networks, in both
normal colonocytes and colon cancer cells that are affected by
butyrate [Mariadason et al., 2000; Iacomino et al., 2001; Tabuchi
et al., 2002, 2006]. A common ﬁnding inmost studies is the blockage
of genes involved in cell cycle regulation (e.g., cyclin D1) and the
transient induction of genes such as p21 (Cip/Waf1), an inhibitor of
Fig. 6. HE staining of butyrate-treatedMeT-5A cells and butyrate-induced cell death in MeT-5A and HT-29 cells. Control MeT-5A cells were grown in the absence of butyrate
(A) or treated with 10mM butyrate for 48 h (B) or 6 days (C). A: Untreated MeT-5A cells formed a regular layer of ﬂattened polygonal cells. Nuclei contain various numbers of
small round-shaped heterochromatin structures and the cytoplasm is faintly stained by eosin. B: Cells that remained attached to the cover slip after treatment with butyrate had
lost most of their cell–cell contacts. Many cells were characterized by irregular shaped, condensed pycnotic nuclei (arrows) and the cytoplasm surrounding the condensed nuclei
showed strong eosinophilia (arrowheads). C: The small fraction of MeT-5A cells that initially survived the butyrate treatment continued to proliferate and cells were able to form
a near-conﬂuent layer. In comparison to untreated cells, more ﬁlamentous structures in the cytoplasm were visible and cell nuclei tended to be slightly larger. Thus, even in the
continuous presence of 10mM butyrate, MeT-5A cells continue to proliferate indicating that butyrate does not have a principal function in the induction of differentiation in
cells of mesothelial origin. Determination of necrotic (D) and apoptotic (E) cell death induced by butyrate in MeT-5A and HT-29 cells, cells of mesothelial and epithelial origin,
respectively. Cells were treated with various butyrate concentrations (0–7.5mM) and cell death was assayed 24 h (E; apoptosis) or 36 h (D; necrosis) later. Cell death was
normalized to untreated control cells (control¼ 1). Values are the average of two independent experiments (mean SD).
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cyclin-dependent protein-kinases. Among the many genes whose
expression is modulated by butyrate, butyrate-responsive elements
(BREs) were identiﬁed in the promoter region of several ones, mostly
by in vitro promoter analysis. The detailed analysis of available BRE
sequences (Fig. 4) allowed us to deduce a consensus sequence that
was rather well conserved in most of the reported BREs and consists
of the sequence GCnGGnnCCA. In genes regulated by butyrate, this
conserved element is often closely spaced to the TATA box region; in
the genes CDKN1A, KLF4,HBG, and CALB2, the BREs are only 4–32
nucleotides upstream of the TATA box and in the CALB1 and CGA
genes, the distance is less than 150 nucleotides. This is unlike
for other elements such as cAMP-responsive (CRE), vitamin
D-responsive (VDRE) or retinoic acid-responsive (RAR and RXR)
elements that are often several kilobases away from the TATA box or
the transcription start site.
CR normally expressed in speciﬁc neurons of the central and
peripheral nerve system as well as in few other cell types, is
aberrantly expressed in several type of tumors, in particular in
poorly differentiated colon tumors [Gotzos et al., 1999] and in
certain mesotheliomas [Doglioni et al., 1996; Gotzos et al., 1996b].
Also in vitro in colon cancer cell lines, diverse expression levels of
CR were observed: low expression in cell lines derived from well-to-
moderately differentiated tumors (e.g., Caco-2) and high expression
in cell lines derived from poorly differentiated ones (HT-29, WiDr,
Co-115/3) [Gotzos et al., 1996a]. This additionally correlated well
with the growth-inhibiting sensitivity to butyrate as evidenced for
Caco-2, HT-29 and analyzed in more detail for Co-115/3 cells. The
latter cells did not only show the highest resistance to the growth-
inhibiting effect of butyrate, but also had the highest CR expression
levels. Based on the previous ﬁnding that addition of butyrate to
cultured colon cancer cells not only blocks cell growth, but at the
same time down-regulates the expression of CR [Schwaller and
Herrmann, 1997; Marilley et al., 2001], we hypothetized that the
promoter region of the CALB2 gene might contain BREs acting as
repressors. Analysis of the promoter region of human, rat and mouse
CALB2 revealed six putative BREs contained in a region of
approximately 1.5 kb upstream of the ﬁrst exon. Globally, the six
BREs (with the exception of BRE2) were highly conserved in the
three species. The functionality of the BREs was analyzed in the
three colon cancer cell lines Co-115/3, HT-29, and Caco-2. A
deletion analysis of the 1.5 kb region revealed to enclose one or
several elements acting as repressors of butyrate-induced luciferase
expression in the region surrounding the TATA box and containing
the BREs 5 and 6. In all the three cell lines essentially identical
results were obtained, that is, a 40% reduction in luciferase activity
after 48 h compared to the control plasmid without the CALB2
region. Mutations in either BRE 5 or BRE 6 reduced the repressor
effect by approximately 50% each indicating that both elements
contribute to the butyrate-induced repression of CR expression.
Since aberrant expression of CR is also the hallmark of
mesotheliomas, in particular of the epithelial type, we used either
the SV40-immortalized cell line MeT-5A or the mesothelioma cell
line ZL34 that both express CR [Henzi et al., 2009] and [Saydan et al.,
2001], respectively. Unlike in colon cancer cells, where butyrate
mainly affects proliferation, doses of>1mM led to massive death of
cells of mesothelial origin starting from the third day of butyrate
treatment. Before this time point, proliferation was similar or even
slightly increased in butyrate-treated cells of mesothelial origin.
While the addition of butyrate to colon cancer cells induces
morphological changes from a pavement-like appearance of
untreated cells to a more ﬂattened morphology with a larger
nucleus and clear cytoplasm, butyrate-treated MeT-5A cells showed
cell swelling, rounding and detachment from the culture dishes
typical for cell death and also signs of apoptosis were detected (e.g.,
pycnotic fragmented nuclei) as described before in the mesothe-
lioma cell lines REN and I-45 [Cao et al., 2001]. In MeT-5A cells
treated with ‘‘tolerable’’ doses of butyrate (1 and 2mM), expression
levels of CR were essentially unchanged. In the reporter assay, the
region containing BREs 5 and 6 did not repress the butyrate-induced
luciferase activity. Thus, in cells of mesothelial origin, the BREs are
non-functional. This came not as a real surprise, since under
physiological conditions, mesothelial cells are probably exposed to
very low butyrate concentrations. In the feces butyrate may reach
levels of 70mmol/g wet weight translating to values of up to 10mM.
Amajority (85–90%) of butyrate is taken up by colonocytes, thereby
providing a substantial energy supply for these cells [Roediger,
1982]. The remaining butyrate ends up in the portal vein and
transiently increases the circulating level of butyrate [Bach Knudsen
et al., 2003]. Before reaching mesothelial cells (e.g., in the
peritoneum) butyrate needs to traverse the endothelium of blood
vessels and then the connective tissue. On the one hand, the colonic
mucosa is constantly exposed to millimolar concentrations of
butyrate, which plays an important role in the homeostasis of the
colonic mucosa by, for example, suppressing cell proliferation,
inducing differentiation and also playing a role in apoptosis. As a
consequence butyrate functions as a physiological signaling
molecule in colonocytes, affecting various cellular processes, also
at the level of transcription. On the other hand, such a physiological
signaling role in cells of mesothelial origin appears rather unlikely,
however it cannot be entirely excluded. Nonetheless, butyrate was
previously shown to increase cell death in mesothelioma cells by
decreasing the levels of the anti-apoptotic protein BCL-XL [Cao
et al., 2001].
What are the implications of the butyrate-induced down-
regulation of CR expression in colon cancer cells? The standard
adjuvant chemotherapy for colon cancer consists of 5-ﬂuorouracil
(5-FU) treatment, nowadays often in combination with oxaliplatin
[Allen et al., 2006]. The success rate of 5-FU treatment alone is rather
low (10–20%), mainly as the result of 5-FU resistance of a small
fraction of cancer cells [Lesufﬂeur et al., 1991] leading to the
recurrence of the tumor [Longley et al., 2006]. An analysis of 5-FU-
sensitive and 5-FU-resitant cells revealed that besides the mRNA of
prostate-derived factor (PDF, a member of the TGF-beta family) and
spermidine/spermine N1-acetyl transferase (SSAT), the one that was
constitutively upregulated was the CALB2 mRNA [Boyer et al.,
2006]. In addition, acute treatment of HT-29 cells with an IC50 dose
of 5-FU or oxaliplatin resulted in a two- to fourfold larger CALB2
signal. In this study this was interpreted as an upregulation of
CALB2mRNA, but in view of the fact that many cells die during the
5-FU treatment, the increase in CALB2 mRNA could also be
considered as an accumulation (selection) of resistant cells with
higher CR expression. Even ‘‘pure’’ cell lines are more heterogeneous
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than previously thought; all four tested clones derived from HT-29
cells differentiated after butyrate treatment, but showed differences
in their response with respect to some of the markers [Stokrova et al.,
2006]. Along the same line, we have previously observed that CR
expression levels in HT-29 or the closely related WiDr cells are not
homogenous and the strongest immunoreactivity is seen in
proliferative cells at the border of cell clusters or in dividing cells
[Gotzos et al., 1992; Cargnello et al., 1996]. In the study by Boyer
et al. [2006] knockdown of CR expression with siRNA did not
affect basal levels of apoptosis evidenced by unchanged PARP
cleavage, but signiﬁcantly reduced programmed cell death when
combined with 5-FU or oxaliplatin. Since the induction of a more
differentiated phenotype in WiDr or HT-29 cells by either butyrate
[Marilley et al., 2001] or glucose starvation [Cargnello et al., 1996],
respectively, goes together with a decrease in CR expression, we
hypothesize that 5-FU and oxaliplatin are more efﬁcient cytotoxic
agents in proliferating cells in vitro than in ones, where the cell cycle
is already entirely blocked. Knockdown of CR expression by
antisense oligo nucleotides in WiDr cells blocks the cycle mainly at
G1/S [Gander et al., 1996]. Thus, this apparent protection against
5-FU cytotoxicity might be due to the cell cycle silencing effect
induced by CR downregulation. In vivo the situation appears to be
different. 5-FU-resistant colon tumors in rats were highly responsive
to a butyrate/IL-2 bi-therapy [Cordel et al., 1997]. The median
survival time of rats with 5-FU resistant tumors was considerably
enhanced by concomitant treatment with butyrate/IL-2. Four out of
ﬁve rats were still alive 250 days after treatment and were
considered cured, while median survival time for rats treated only
with 5-FU was 85 days. Also growth of human colorectal cancers
grafted into nude mice was stronger inhibited with the combination
of 5-FU and the stable butyrate derivative (3n-But) than with 5-FU
alone irrespective of their p53 and microsatellite instability status
[Bras-Goncalves et al., 2001]. The main effect was a blockage of cell
proliferation without affecting cell differentiation and signiﬁcantly
enhanced apoptosis, while treatment with 5-FU or 3n-But alone
stopped the cycle in S and in G1 phase, respectively. We postulate
that the gradual down-regulation of CR by butyrate would slow
down proliferation, and possibly shift the cells towards a more
differentiated phenotype that renders the surviving 5-FU-resistant
tumor cells again sensitive to the action of 5-FU. Thus, the better
survival of rats subjected to the 5-FU/butyrate combination may lie
in the suppression of CR expression and/or the modulation of
expression of other butyrate-sensitive genes through the action of
butyrate. Whether this therapy might be also successfully applied in
humans remains to be shown, but the fact the CALB2 promoter is
directly responsive to butyrate makes the CALB2 gene a putative
target for a novel cancer therapy.
An unexpected link between colon cancer and Ca2þ signaling was
provided by Bush et al. [2007]. One of the genes induced in early
stage colon cancer by butyrate is PPARg known to inhibit tumor cell
growth through induction of G1-phase arrest, leading to irreversible
withdrawal from the cell cycle. A microarray study of cells treated
with the PPARg agonist thiazolidinedione revealed a link between
PPARg and Down syndrome critical region 1 (DSCR1), an
endogenous calcineurin inhibitor. DSCR1 blocks dephosphorylation
of NFATc, thereby preventing the translocation of the activated form
to the nucleus. Downregulation of DSCR1 suppresses the inhibition
of proliferation exerted by PPARg. A link between PPARg,
mitochondria and Ca2þ signaling has been shown before, but
this additional link via DSCR1 and calcineurin indicates
that altered Ca2þ regulation may also have a distinct role in
transformation of epithelial cells to colon cancer cells. In addition,
PPAR-ligands, independently from their PPAR binding speciﬁcity,
can induce a derangement of the mitochondrial respiratory chain
resulting from a strong inhibition of oxidative phosphorylation
complexes including complexes IIþ III, IV, V, and VI [Nadanaciva
et al., 2007]. These complexes are necessary to maintain the
electrochemical gradient across the mitochondria membrane that is
used to drive the mitochondrial Ca2þ uptake. Thus, PPAR agonists
may have an additional effect on Ca2þ signaling in cancer cells
via blocking mitochondrial Ca2þ uptake. Furthermore, butyrate
upregulates plasma membrane calcium ATPase (PMCA) isoform 4 in
HT-29 cells, but not affecting PMCA1 [Aung et al., 2007], in further
support that speciﬁc alterations in Ca2þ signaling may play a role in
colon cancer tumorigenesis. Thus, the Ca2þ-buffer CR also reported
to possibly have additional ‘‘Ca2þ sensor’’ functions [Billing-
Marczak and Kuznicki, 1999; Faas et al., 2007] may be implicated
directly or indirectly in affecting colon cancer cell Ca2þ signaling
and thereby exerting a protective effect against drug-induced
cytotoxicity.
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